📰 Pharmaceutical Intelligence News
Page 2 - Pharmaceutical Intelligence News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharmaceutical Intelligence. Real-time updates on events, politics, business and more.
December 21, 2023
Etimupepimut is under clinical development by IO Biotech and currently in Phase II for Polycythemia Vera.
December 5, 2023
Dalzanemdor is a small molecule commercialized by Sage Therapeutics, with a leading Phase III program in Huntington Disease.
December 4, 2023
Pidnarulex is under clinical development by Senhwa Biosciences and currently in Phase I for Solid Tumor.
December 4, 2023
Pitolisant hydrochloride is under clinical development by Harmony Biosciences and currently in Phase II for Prader-Willi Syndrome (PWS).
November 5, 2023
Dalzanemdor is a small molecule commercialized by Sage Therapeutics, with a leading Phase III program in Huntington Disease.
November 5, 2023
Laronidase is a recombinant enzyme commercialized by JCR Pharmaceuticals, with a leading Phase II program in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ).
November 5, 2023
Barzolvolimab is a monoclonal antibody commercialized by Celldex Therapeutics, with a leading Phase II program in Eosinophilic Esophagitis.
November 5, 2023
Eculizumab is under clinical development by Alexion Pharmaceuticals and currently in Phase II for Subarachnoid Hemorrhage.
November 4, 2023
MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Bladder Cancer.
November 4, 2023
CLN-617 is under clinical development by Cullinan Oncology and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma.